NasdaqGS:UTHRBiotechs
United Therapeutics Advances IPF Program With TETON-2 And PROLIFIC Milestones
United Therapeutics reported positive TETON-2 study results for inhaled treprostinil in idiopathic pulmonary fibrosis (IPF).
The data indicate a potential role for inhaled treprostinil in helping stabilize lung function for IPF patients.
The FDA qualified the PROLIFIC Risk Score, a tool designed to identify IPF patients at higher risk of rapid progression and support more targeted clinical trials.
United Therapeutics (NasdaqGS:UTHR) is drawing attention as it pairs clinical momentum with a...